2020 CGA
Annual Meeting
Thank you for attending our virtual CGA Annual Meeting on November 14-15, 2020.
​
All General Sessions, Named Lectureships and Live Abstract Presentations are on the meeting app and instructions to access were emailed. Please reach out to cga@pacemedcom.com with any questions on how to access.
November 14-15, 2020
The CGA Annual Meeting will provide critical data and information designed to keep clinicians and scientists up-to-date on new developments in hereditary gastrointestinal cancer research, including implications for physicians, psychologists, nurses, and genetic counselors to make informed decisions about the prevention, diagnosis, and treatment of patients with hereditary gastrointestinal cancer syndromes.
Who Should Attend
The 2020 CGA Annual Meeting will be directed to colorectal surgeons, medical oncologists, gastroenterologists, internists, gynecologists, researchers, geneticists, nurses, colorectal cancer registry coordinators, genetic counselors, psychologists and other professionals involved in the care of individuals with hereditary gastrointestinal cancer, including colorectal, esophageal, pancreatic, gastric, and small bowel cancers.
Objectives
After completing this activity, participants will be able to do the following:
-
Summarize recent research on the basic biology of gastrointestinal cancer development, including modifiers of the hereditary phenotypes
-
Describe potential implications for clinical practice
-
Implement new approaches to screening and preventing gastrointestinal cancers
-
Summarize the evidence for new diagnostics, devices, and pharmaceuticals
-
Describe the impact of newly discovered genes and the use of recently introduced gene panels to diagnose and manage hereditary gastrointestinal cancer syndromes
-
Institute use of clinical and genetic modifiers of the hereditary cancer risk in their clinical practice
-
Define the changing care models for diagnosis and management of various hereditary cancer syndromes
-
List the surgical approaches to hereditary gastrointestinal cancer syndromes for both treatment and prophylaxis
-
Describe patient criteria for referral for surgery that offers optimal outcomes
Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS) and the Collaborative Group of the Americas on Inherited Colorectal Cancer. RMCHCS is accredited by the NMMS to provide continuing medical education for physicians.
RMCHCS designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Society of Genetic Counselors (NSGC) has authorized Collaborative Group of the Americas on Inherited Gastrointestinal Cancer to offer up to 1.6 CEUs or 16 Category 1 contact hours for the activity 2020 CGA Annual Meeting. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.
​
This educational activity is supported by educational grants from AstraZeneca and Pfizer.
Registration & Agenda
Sponsorship Opportunities
©2023 by Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC)